ArticleDiscover oncology2025
FAM64A silencing inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition in ovarian cancer cells via activating Hippo pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting FAM64A: a promising strategy to halt liver cancer angiogenesis and enhance immunity.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOvarian cancer (OC) is a highly aggressive malignancy in females. We aim to investigate the potential gene target and examine its impact on OC.
methodsHub genes were determined using protein-protein interaction networks based on differently expressed genes in GSE12470 and GSE14407 datasets. The impact of FAM64A on the malignant phenotype of OC cells was evaluated by cell counting kit-8, 5-ethynyl-2'-deoxyuridine staining, wound healing, and transwell assays. The epithelial-mesenchymal transition (EMT) process was assessed by determining the protein expression of E-cadherin, N-cadherin, and Vimentin.
resultsWe identified the 18 hub genes of OC with substantial predictive value. FAM64A was selected as a candidate gene. The silencing of FAM64A suppressed the viability (si-NC: 0.78 ± 0.04, 0.95 ± 0.08; si-FAM64A: 0.58 ± 0.05, 0.64 ± 0.11), proliferation (si-NC: 100.00 ± 9.36, 100.00 ± 14.70; si-FAM64A: 34.79 ± 8.88, 44.55 ± 4.91), migration (si-NC: 61.92 ± 8.06, 60.08 ± 5.22; si-FAM64A: 45.88 ± 8.36, 37.78 ± 7.29), and invasion (si-NC: 130.00 ± 10.34, 144.00 ± 13.40; si-FAM64A: 81.00 ± 16.99, 115.60 ± 13.30) of A2780 and SKOV3 cells. FAM64A silencing reduced the EMT in OC cells. The Hippo pathway was identified as the central pathway implicated in the regulatory role of FAM64A in OC. The silencing of FAM64A caused an increase in the protein expression within the Hippo pathway in both A2780 and SKOV3 cells.
conclusionKnockdown of FAM64A emerges as a promising therapeutic target for OC, exerting an inhibitory role in OC by activating the Hippo pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.